Citations

Clear

5 citation(s) found for "Stevens, Michael".

Staying Safe for the Long Haul: A Health Belief Model Analysis of COVID-19 Preventive Behaviors Through the Lens of Long COVID
Guidry, Jeanine P. D. , Burton, Candace W. , Perrin, Paul B. , Pinto, Melissa D. , Chelimsky, Thomas , Gharbo, Raouf, Carlyle, Kellie E. , Burton, Candace W , Pinto, Melissa D , Laestadius, Linnea Irina , Miller, Carrie A. , Stevens, Michael , Cuddeback, Gary S.

Mayo Clinic

Clinical Nursing Research | August 6, 2025 | Volume: 34 | Issue: 6 | Pages: 267-276

10.1177/10547738251360170 | PMID 40764982 Get It

Health problems associated with post-acute COVID-19, also known as “Long COVID,” range from mild to severe. The best defense against this potentially serious condition is to prevent COVID-19 infection and reinfection. The same preventive measures for COVID-19 may be used to help prevent the spread of Long COVID. This study used the Health Belief Model (HBM) to examine whether and how public understanding and awareness of Long COVID and its prevention shape the adoption of COVID-19 preventive behaviors. N = 605 English-speaking U.S.-based adults were recruited via Qualtrics. Predictors of intention to carry out COVID-19 preventive behaviors were investigated. Outcomes included behaviors relevant to preventing both acute and Long COVID. Across all models, except the one examining intent to get a vaccine booster, Black respondents were more likely than White respondents to express intent to carry out COVID-19 preventive behaviors. In addition, HBM constructs added significantly to the regression models. Susceptibility to Long COVID was significant for all behavioral outcomes (all p s < .05), self-efficacy for wearing a mask ( p < .001), and self-efficacy for testing for COVID-19 after exposure and before a social event ( p s < .001). In addition, perceived benefits for Long COVID prevention predicted intent of mask-wearing ( p < .001), testing before a social event ( p = .002), and getting a vaccine booster ( p = .001). Perceived severity of Long COVID did not significantly predict adherence to preventive behaviors. U.S. adults are more likely to express intent to carry out COVID-19 preventive behaviors, such as masking and receiving booster vaccines, when they report feeling greater susceptibility to Long COVID as well as greater self-efficacy for engaging in these preventive behaviors. Public health messaging about Long COVID with incorporation of HBM constructs may be an effective means of increasing continued recommended COVID-19 preventive behaviors, which also hold co-benefits for prevention of infections, such as influenza and measles, as well as emerging viruses such as avian flu.
Structure-based design and characterization of Parkin-activating mutations
Stevens, Michael , Croteau, Nathalie , Eldeeb, Mohamed A. , Zeng, Zhi Wei , Toth, Rachel , Durcan, Thomas M. , Springer, Wolfdieter , Muqit, Miratul M. K. , Trempe, Jean‐François , Toth, Rachel , Springer, Wolfdieter , Fon, Edward A , Muqit, Miratul Mk , Trempe, Jean-François , Antico, Odetta

Mayo Clinic

Life Science Alliance | March 20, 2023 | Volume: 6 | Issue: 6 | Pages: e202201419

10.26508/lsa.202201419 | PMID 36941054 Get It

Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Localized vagina/uterus rhabdomyosarcoma (VU RMS): Results of a pooled analysis from four international cooperative groups.
Anderson, James Robert, Schwob, Dominique, Rodeberg, David A. , Martelli, Hélène , Walterhouse, David , Arndt, Carola A.S., Rey, Annie, Oberlin, Odile, Meder, Christine, Minard‐Colin, Véronique , Anderson, James Robert, Bisogno, Gianni , Stevens, Michaël C.G. , Ferrari, Andrea , Salvo, Gian Luca De , Hawkins, Douglas S.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10063-10063

10.1200/jco.2015.33.15_suppl.10063 Get It

Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups
Minard‐Colin, Véronique , Walterhouse, David , Bisogno, Gianni , Martelli, Hélène , Anderson, James R. , Rodeberg, David A. , Ferrari, Andrea , Jenney, Meriel , Wolden, Suzanne L. , Salvo, Gian Luca De , Arndt, Carola, Gallego, Soledad , Schwob, Dominique, Haie‐Méder, Christine, Bergeron, Christophe , Stevens, Michaël C.G. , Oberlin, Odile, Hawkins, Douglas S. , Wolden, Suzanne , Hawkins, Douglas S , Bisogno, Gianni , Merks, Johannes H M

Mayo Clinic

Pediatric Blood & Cancer | May 21, 2018 | Volume: 65 | Issue: 9 | Pages: No page available

10.1002/pbc.27096 | PMID 29781567 Get It

AbstractBackgroundVaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed.ProcedureFrom 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty‐eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG).ResultsTen‐year event‐free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty‐one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery.ConclusionsAbout half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy.
Late Effects in 164 Patients With Rhabdomyosarcoma of the Bladder/Prostate Region: A Report From the International Workshop
Raney, Beverly, Anderson, James R. , Jenney, Meriel , Arndt, Carola, Brecht, Ines B. , Carli, Modesto, Bisogno, Gianni , Oberlin, Odile, Rey, Annie, Treuner, Jörn, Ullrich, Fred , Stevens, Michaël C.G. , Bisogno, Gianni

Mayo Clinic

Journal of Urology | October 26, 2006 | Volume: 176 | Issue: 5 | Pages: 2190-2195

10.1016/j.juro.2006.07.064 | PMID 17070290 Get It